Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVXSWX:CMHC -2.89%81 3-Year Dividend Growth Rate is 26.80% as of Jun. 2026, which is 33% above its 10-year median of 20.10. GuruFocus rates XSWX:CMHC with a GF Score™ of 81/100 and a GF Value™ of CHF40.77 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 349 Drug Manufacturers companies, Cosmo NV ranks better than 78.8% on this metric.
The historical rank and industry rank for Cosmo NV's 3-Year Dividend Growth Rate or its related term are showing as below:
XSWX:CMHC'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 13.4 Med: 20.1 Max: 26.8
Current: 26.8
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Cosmo NV was 26.80% per year. The lowest was 13.40% per year. And the median was 20.10% per year.
XSWX:CMHC's 3-Year Dividend Growth Rate is ranked better than 78.8% of 349
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs XSWX:CMHC: 26.80
During the past 12 months, Cosmo NV's average Dividends Per Share Growth Rate was -49.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 26.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Cosmo NV was 1.10. The lowest was 0.25. And the median was 0.91.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Cosmo NV Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EUR 2.100000
2026-04-24
2026-04-27
2026-05-11
Cash Dividend
annually
EUR:CHF 0.915088
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Cosmo NV's Dividend Yield (%) for Today is calculated as
Current Share Price is CHF57.10.
Cosmo NV's Dividends per Share for the trailing twelve months (TTM) ended in Today is CHF1.9216848.
During the past 13 years, the highest Dividend Yield of Cosmo NV was 4.03%. The lowest was 0.84%. And the median was 1.56%.
Good Sign:
Cosmo NV stock Dividend Yield % is close to 1-year high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV 3-Year Dividend Growth Rate Related Terms>
XSWX:CMHC vs LLY, JNJ, ABBV: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Cosmo NV's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 26.80% mean?
Cosmo NV (XSWX:CMHC) has a 3-Year Dividend Growth Rate of 26.80% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Cosmo NV and its competitors. This is 33% above median its historical median of 20.10. Over the past decade, Cosmo NV's 3-Year Dividend Growth Rate has ranged from 13.40 to 26.80. According to the industry distribution chart, Cosmo NV ranks #74 out of 349 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Cosmo NV's 3-Year Dividend Growth Rate too high?
Cosmo NV's current 3-Year Dividend Growth Rate of 26.80% is 33% above median its 10-year median of 20.10. Over the past 10 years, this metric has ranged from a low of 13.40 to a high of 26.80. The Drug Manufacturers industry median 3-Year Dividend Growth Rate is 7.70. Cosmo NV's value of 26.80% is 248.1% above this industry median. Based on the distribution chart, Cosmo NV ranks #74 out of 349 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's 3-Year Dividend Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #74 out of 349 companies for 3-Year Dividend Growth Rate. This places Cosmo NV in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year Dividend Growth Rate is 7.70. Cosmo NV's value of 26.80% is 248.1% above this benchmark. Historically, Cosmo NV's own 3-Year Dividend Growth Rate has ranged from 13.40 to 26.80 over the past decade. While the company's 10-year median is 20.10 vs. the industry median of 7.70, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current 3-Year Dividend Growth Rate of 26.80% is 248.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current 3-Year Dividend Growth Rate is 26.80%, which is 33% above median its own 10-year median of 20.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:CMHC) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.77, compared to a current price of CHF57.10 — trading 40.1% above its estimated fair value. The current 3-Year Dividend Growth Rate is 26.80%, which is 33% above median its 10-year median of 20.10 and 248.1% above the Drug Manufacturers industry median of 7.70. Cosmo NV's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Cosmo NV (XSWX:CMHC), the current 3-Year Dividend Growth Rate is 26.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:CMHC) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF57.10 is trading 40.1% above its estimated GF Value™ of CHF40.77.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:CMHC:
3-Year Dividend Growth Rate: 26.80% (33% above median its 10-year median of 20.10)
GF Value™: CHF40.77 vs. price of CHF57.10 (40.1% above fair value)
Industry Position: 248.1% above the Drug Manufacturers median (#74 of 349)
No single metric tells the full story. See the XSWX:CMHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
81GF Score
Get the complete analysis for XSWX:CMHC
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CMHC has been successfully added to your 
